Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response

BACKGROUND/AIMS: Erlotinib and gemcitabine combined chemotherapy is becoming the treatment of choice in advanced pancreatic cancer. We evaluated the effectiveness of treatment with erlotinib plus gemcitabine and the prognostic factors for chemotherapeutic response in Korean pancreatic cancer patient...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Park, Semi, Chung, Moon Jae, Park, Jeong Youp, Chung, Jae Bock, Bang, Seungmin, Park, Seung Woo, Song, Si Young
Materialtyp: Artigo
Språk:Inglês
Publicerad: The Korean Society of Gastroenterology; the Korean Society of Gastrointestinal Endoscopy; the Korean Association for the Study of the Liver; the Korean Society of Neurogastroenterology and Motility; Korean Association for the Study of Intestinal Diseases; Korean College of Helicobacter and Upper Gastrointestinal Research; Korean Pancreatobiliary Association; Korean Society of Gastrointestinal Cancer 2013
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3782678/
https://ncbi.nlm.nih.gov/pubmed/24073321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5009/gnl.2013.7.5.611
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk